NYSE:BHC

Bausch Health Companies Stock Forecast, Price & News

$28.21
+2.10 (+8.04 %)
(As of 09/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.25
$28.50
50-Day Range
$25.04
$29.65
52-Week Range
$14.86
$34.80
Volume5.01 million shs
Average Volume3.37 million shs
Market Capitalization$10.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
30 days | 90 days | 365 days | Advanced Chart
Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies logo

About Bausch Health Companies

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.62 out of 5 stars

Medical Sector

23rd out of 1,352 stocks

Pharmaceutical Preparations Industry

7th out of 665 stocks

Analyst Opinion: 2.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

Is Bausch Health Companies a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Bausch Health Companies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View analyst ratings for Bausch Health Companies
or view top-rated stocks.

What stocks does MarketBeat like better than Bausch Health Companies?

Wall Street analysts have given Bausch Health Companies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bausch Health Companies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Bausch Health Companies
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) announced its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.02. The company earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 1,271.62% and a negative net margin of 15.18%.
View Bausch Health Companies' earnings history
.

How has Bausch Health Companies' stock been impacted by Coronavirus?

Bausch Health Companies' stock was trading at $18.45 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHC stock has increased by 52.9% and is now trading at $28.21.
View which stocks have been most impacted by COVID-19
.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.40 billion-$8.60 billion, compared to the consensus revenue estimate of $8.64 billion.

What price target have analysts set for BHC?

8 brokerages have issued twelve-month price objectives for Bausch Health Companies' stock. Their forecasts range from $17.00 to $55.00. On average, they anticipate Bausch Health Companies' stock price to reach $34.40 in the next year. This suggests a possible upside of 21.9% from the stock's current price.
View analysts' price targets for Bausch Health Companies
or view top-rated stocks among Wall Street analysts.

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:
  • Joseph C. Papa, Chairman & Chief Executive Officer
  • Thomas J. Appio, President & Co-Head-Bausch Lomb International
  • Sam Eldessouky, CFO, Chief Accounting Officer, SVP & Controller
  • Tage Ramakrishna, Chief Medical Officer, President-R&D
  • Christina M. Ackermann, Executive Vice President & General Counsel

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies CEO Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among Bausch Health Companies' employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.60%), Goldentree Asset Management LP (2.28%), Price T Rowe Associates Inc. MD (2.19%), Laurion Capital Management LP (1.90%), Morgan Stanley (1.57%) and Morgan Stanley (1.57%). Company insiders that own Bausch Health Companies stock include Amy B Wechsler, Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Russell Barrans, Sam Eldessouky, Schutter Richard U De and William D Humphries.
View institutional ownership trends for Bausch Health Companies
.

Which institutional investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Morgan Stanley, Morgan Stanley, BlackRock Inc., Royal Bank of Canada, Skandinaviska Enskilda Banken AB publ, Credit Suisse AG, and Wells Fargo & Company MN. Company insiders that have sold Bausch Health Companies company stock in the last year include Amy B Wechsler, Christina Ackermann, Sam Eldessouky, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies
or view top insider-selling stocks.

Which institutional investors are buying Bausch Health Companies stock?

BHC stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Price T Rowe Associates Inc. MD, Fir Tree Capital Management LP, Balyasny Asset Management LLC, Susquehanna International Group LLP, Capula Management Ltd, Guardian Capital LP, and Laurion Capital Management LP. Company insiders that have bought Bausch Health Companies stock in the last two years include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Russell Barrans, and Schutter Richard U De.
View insider buying and selling activity for Bausch Health Companies
or or view top insider-buying stocks.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $28.21.

How much money does Bausch Health Companies make?

Bausch Health Companies has a market capitalization of $10.11 billion and generates $8.03 billion in revenue each year. The company earns $-560,000,000.00 in net income (profit) each year or $3.99 on an earnings per share basis.

How many employees does Bausch Health Companies have?

Bausch Health Companies employs 21,600 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.bauschhealth.com.

Where are Bausch Health Companies' headquarters?

Bausch Health Companies is headquartered at 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at (514) 744-6792 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.